Investment

7 MANAGEMENT DISCUSSION AND ANALYSIS 85 CORPORATE GOVERNANCE REPORT 85 CORPORATE GOVERNANCE REPORT 119 INDEPENDENT AUDITOR'S REPORT 119 INDEPENDENT AUDITOR’S REPORT 128 CONSOLIDATED INCOME STATEMENT 128 CONSOLIDATED INCOME STATEMENT 129 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 130 CONSOLIDATED STATEMENT OF FINANCIAL POSITION 133 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 137 CONSOLIDATED STATEMENT OF CASH FLOWS 139 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1...

Incorporated in the Cayman Islands with limited liability smart communication inspires 2024 P Interim Report 33 Financial Performance Highlights Financial Performance Highlights 88 Management Discussion and Analysis 22 Report on Review of Interim Financial Information 23 Condensed Consolidated Income Statement 23 Condensed Consolidated Income Statement 24 Condensed Consolidated Statement of Comprehensive Income 24 Condensed Consoli...

As of March 31,2022 As of March 31,2023 Cause of Occurrence Net cash provided by (used in) 2,505 2,927 Cash flows from operating operating activities activities Net cash provided by (used in) (1,183) (1,417) Income before income taxe investing activities Depreciation +902 +3,173 Free cash flow 1,321 ...

Meidensha Corporation’s supplementary financial information for the fiscal year ended March 31, 2025, details a period of significant growth in profitability and order intake. The company reported consolidated net sales of 301.1 billion yen, representing a 4.6% increase over the previous fiscal year. More notably, operating income surged by 169% to 21.5 billion yen, while net income attributable to owners of the parent rose by 165% to 18.5 billion yen. Total orders received reached 383.6 billion yen, a 16.5% increase, signaling strong demand across its core business segments.

The company operates across several key segments, including Power Infrastructure, Public, Industrial & Commercial Sector, Mobility & Electrical Components, and Field Service Engineering. The Power Infrastructure and Public, Industrial & Commercial sectors were primary drivers of growth, with both segments seeing substantial increases in order volume. While the Mobility & Electrical Components segment experienced a decline in net sales, it achieved a notable turnaround in operating income, moving from 196 million yen in the previous year to 1.1 billion yen. The Field Service Engineering segment also demonstrated strong performance, contributing 9.9 billion yen in operating income.

Looking ahead to the fiscal year ending March 2026, the company projects continued growth with forecasted net sales of 335 billion yen. Planned capital expenditures are expected to nearly double to 20 billion yen, alongside increased investments in research and development, which are projected to reach 13.5 billion yen. These figures reflect a strategic focus on scaling operations and enhancing technological capabilities following the successful integration of business segments after the previous year's merger with MEIDEN SHOJI Co., Ltd.

Issued: Wednesday,30 April 2025, London, U.K. GSK makes strong start to 2025 with growth in sales, profits and earnings Specialty Medicines growth drives Q1 performance • Total Q1 sales £7.5 billion +2% AER; +4% CER • Specialty Medicines sales £2.9 billion (+17%); Respiratory, Immunology and Inflammation £0.8 billion (+28%); Oncology £0.4 billion (+53%); HIV sales £1.7 billion (+7%) • Vaccines sales £2.1 billion (-6%); Shingrix £0.9 billion (-7%); Meningitis vaccines £0.4 billion (+2...

alth Group Reports First Quarter 20a UnitedHealth Group Reports First Quarter 2025 Results and Revises Full Year Guidance • Revised 2025 Earnings Outlook to $24.65 to $25.15 Per Share, Adjusted Earnings • First Quarter Earnings were $6.85 Per Share, Adjusted Earnings $7.20 Per Share • Revenues of $109.6 Billion Grew $9.8 Billion Year-Over-Year • Consumers Served by UnitedHealthcare Increased by 780,000 Year to Date • Optum Health Continues to Expect to Serve 650,000 New Value...

Andrew Peller Limited, Canada’s largest publicly traded wine producer, maintains a robust market position through a diversified portfolio of approximately 50 brands ranging from ultra-premium to value segments. The company operates across Canada with a significant asset base exceeding $500 million, encompassing over 600 acres of owned estates and vineyards in Ontario and British Columbia, alongside modern production facilities. With a history spanning 46 years of dividend payments, the organization focuses on sustained long-term value creation through operational efficiency, brand innovation, and the strategic monetization of non-core assets.

Financial performance for the first quarter of fiscal year 2026 demonstrates positive momentum, with EBITA reaching $16.1 million, a 25.4% increase compared to the same period in the previous year. This growth was supported by a 400-basis-point expansion in margins, bringing the quarterly margin to 42.4% on $99.2 million in sales. These results follow a strong fiscal year 2025, which saw annual revenue of $389.6 million and a 25% year-over-year increase in EBITA. The company’s strategic priorities include achieving above-category revenue growth, further margin expansion, and reducing debt levels to a target range of 2.5x to 3.0x.

The company leverages a national distribution network of over 11,000 points, including liquor boards, hospitality venues, and retail channels. Key growth drivers involve continued investment in premiumization, the expansion of "better-for-you" and craft beverage alcohol categories, and the development of wine-focused economic clusters. By integrating estate winery experiences—such as the highly visited Peller Estates and Trius—with a broad retail presence, the company aims to capitalize on the economic development potential of Canada’s primary wine regions while maintaining a disciplined approach to capital allocation and debt reduction.

Bristol-Myers Squibb’s first-quarter 2025 results demonstrate a strategic transition toward its growth portfolio, which achieved a 16% year-over-year increase in net sales. While total global net sales reached $11.2 billion, representing a 6% decline compared to the previous year, the company’s performance was bolstered by strong demand for key assets such as Opdivo, Breyanzi, and Camzyos. The company continues to navigate the impact of generic competition on legacy products, including Revlimid, Sprycel, and Pomalyst, while simultaneously advancing a robust pipeline of clinical and regulatory milestones.

Financial execution remains disciplined, with the company raising its full-year 2025 guidance for both total revenues and non-GAAP earnings per share. The updated revenue outlook of $45.8 billion to $46.8 billion reflects favorable foreign exchange impacts and stronger-than-anticipated performance in the legacy portfolio. Non-GAAP diluted earnings per share are now projected in the range of $6.70 to $7.00. The company maintains a focus on capital allocation, prioritizing debt reduction—having achieved approximately $6 billion in paydowns toward a $10 billion target—while sustaining its commitment to shareholder dividends and share repurchases.

Operational highlights for the quarter include the successful U.S. launch of Opdivo Qvantig and continued volume growth for established oncology and immunology treatments. The company is entering a data-rich period through 2027, with multiple pivotal data readouts expected for new molecular entities and life-cycle management programs. By leveraging improved market access and maintaining a strong balance sheet, the organization aims to sustain its long-term growth trajectory despite ongoing macroeconomic and regulatory challenges.

The Home Depot maintains its position as the world’s largest home improvement retailer, operating a vast network of 2,350 retail stores across the United States, its territories, Canada, and Mexico. The company’s recent financial performance reflects a period of steady scale, characterized by $39.9 billion in total sales and a 9.4 percent increase in sales growth. While comparable store sales experienced a slight contraction of 0.3 percent, the firm reported a diluted earnings per share of $3.45, which rises to $3.56 on an adjusted basis. These figures underscore a strategic commitment to sustained investment aimed at capturing additional market share and enhancing associate engagement.

Operational focus remains centered on digital integration and product expansion to drive customer success. Digital platforms have seen an 8 percent increase in comparable sales, bolstered by the implementation of generative AI tools like Magic Apron to assist shoppers. Furthermore, the company is diversifying its inventory through exclusive partnerships, such as the agreement to carry Kilz-branded primer products, and is actively innovating its live goods offerings to improve gardening outcomes for consumers.

The company’s geographic footprint remains extensive, with 2,028 locations in the U.S. and its territories, 182 in Canada, and 140 in Mexico. By leveraging its physical store infrastructure alongside these digital and product-based enhancements, the organization aims to maintain its competitive edge in the home improvement sector. The current strategy emphasizes a blend of traditional retail strength and technological modernization to ensure long-term operational resilience and customer satisfaction across all international markets.

The first quarter of 2025 for Stellantis was characterized by a challenging commercial transition, resulting in a 9% decline in consolidated shipments to 1.2 million units and a 14% decrease in net revenues to €35.8 billion. These results were primarily driven by lower production volumes in North America due to extended holiday downtime, product transition impacts, and price normalization. Despite these headwinds, the company reported early signs of recovery, including a 190-basis-point sequential increase in EU30 market share and an 82% year-over-year surge in U.S. retail order intake for March 2025.

The company is currently executing a significant product wave, featuring the launch of 20 all-new or upgraded nameplates, including refreshed Ram 2500 and 3500 trucks. However, due to heightened uncertainties regarding evolving tariff policies and their potential impact on the competitive environment, management has suspended its 2025 financial guidance. The company is actively managing these risks by calibrating production, engaging with North American government officials, and adjusting inventory levels to protect profitability.

Geographically, performance varied significantly across regions. North America faced a 25% decline in net revenues, while Enlarged Europe saw a 3% decrease. Conversely, South America demonstrated resilience with a 6% revenue increase and maintained a market share of 23.8%. The company continues to monitor market pricing trends and is re-assessing capital spending plans to navigate the current volatility. This report reflects a strategic focus on stabilizing core operations while managing the transition toward a modernized product portfolio amidst a complex global trade landscape.